CVM 11.22 ▼ -5.16% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    CEL-SCI Corporation

    AMEX: CVM · Real-Time Price · USD
    11.22
    -0.61 (-5.16%)
    At close: Sep 04, 2025, 10:10 AM
    -5.16%
    Bid 11.18
    Market Cap 77.22M
    Revenue (ttm) 5.95M
    Net Income (ttm) -25.42M
    EPS (ttm) -9.13
    PE Ratio (ttm) -1.23
    Forward PE -0.44
    Analyst n/a
    Ask 11.26
    Volume 90,187
    Avg. Volume (20D) 836,732
    Open 12.22
    Previous Close 11.83
    Day's Range 11.15 - 12.53
    52-Week Range 1.98 - 39.30
    Beta 0.54

    About CVM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CVM
    Website n/a
    Full Company Profile
    1 week ago
    -28.6%
    CEL-SCI shares are trading lower after the company... Unlock content with Pro Subscription
    1 month ago
    -22.93%
    CVM stock has given up its prior gain. CEL-SCI shares were trading higher after the company announced it signed a partnership with a Saudi Arabian pharma and healthcare company.
    news image

    5 days ago · businesswire.com

    CEL-SCI Announces Closing of $10 Million Public Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.

    news image

    1 week ago · businesswire.com

    CEL-SCI Announces Pricing of $10 Million Public Offering

    VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $10 million public offering.

    news image

    1 week ago · businesswire.com

    CEL-SCI Announces Proposed Public Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces proposed public offering.

    news image

    2 weeks ago · businesswire.com

    CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal third quarter 2025 financial results.

    news image

    3 weeks ago · businesswire.com

    CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.

    news image

    1 month ago · businesswire.com

    CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.

    news image

    1 month ago · businesswire.com

    CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.

    news image

    2 months ago · businesswire.com

    FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine.

    Add to Watchlist